Kenneth S. Lown

4.4k citations

23 papers · 3.0k indexed · 1 hit paper · h-index 19

Pharmacology top 0.05%
Oncology top 2%
Pediatrics, Perinatology and Child Health top 1%
Molecular Biology
Pharmacology top 5%

Co-authors: Paul B. Watkins Phyllissa Schmiedlin‐Ren D. Kim Turgeon Kenneth E. Thummel Joseph C. Kolars Steven Wrighton Robert M. Merion Mary F. Paine
Topics: Pharmacogenetics and Drug Metabolism (12 papers)Drug Transport and Resistance Mechanisms (9 papers)Renal Transplantation Outcomes and Treatments (4 papers)
Cited by: Pharmacology Transplantation Oncology
Journals: Journal of Clinical Investigation Gastroenterology Molecular Pharmacology
Partner nations: United States United Kingdom Canada

In The Last Decade

Kenneth S. Lown

23 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*

1997 576 citations Kenneth S. Lown, Robert R. Mayo et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Kenneth S. Lown

Since Specialization

Citations

This map shows the geographic impact of Kenneth S. Lown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth S. Lown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth S. Lown more than expected).

Fields of papers citing papers by Kenneth S. Lown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth S. Lown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth S. Lown. The network helps show where Kenneth S. Lown may publish in the future.

Co-authorship network of co-authors of Kenneth S. Lown

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth S. Lown. A scholar is included among the top collaborators of Kenneth S. Lown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth S. Lown. Kenneth S. Lown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test 2019 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Paul B. Watkins,Steven Wrighton,Jeffrey L. Barnett,Kenneth S. Lown,Kent L. Kunze,Kenneth E. Thummel,Joseph C. Kolars	11
2	Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans 2002 ·American Journal of Physiology-Endocrinology and Metabolism ·Craig A. Jaffe,D. Kim Turgeon,Kenneth S. Lown,Roberta DeMott-Friberg,Paul B. Watkins	107
3	Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers 1999 ·Gastroenterology ·(unknown),Kenneth S. Lown,Mary F. Paine,(unknown),R M Santella,(unknown),(unknown),Arthur Greenberg,Paul B. Watkins	101
4	Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction 1999 ·Drug Metabolism and Disposition ·Stephen D. Hall,Kenneth E. Thummel,Paul B. Watkins,Kenneth S. Lown,Leslie Z. Benet,Mary F. Paine,Robert R. Mayo,D. Kim Turgeon,David G. Bailey,Robert J. Fontana,Steven Wrighton	86
5	Drug-induced liver disease 1998 ·Current Opinion in Gastroenterology ·Kenneth S. Lown	7
6	Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. 1998 ·PubMed ·Kenneth S. Lown,Mita Ghosh,Paul B. Watkins	50
7	Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. 1997 ·Journal of Clinical Investigation ·Kenneth S. Lown,David G. Bailey,Robert J. Fontana,(unknown),(unknown),(unknown),Marc B. Brown,Wei Guo,Paul B. Watkins	495
8	Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporinebreakdown → 1997 ·Clinical Pharmacology & Therapeutics* ·Kenneth S. Lown,Robert R. Mayo,Alan B. Leichtman,(unknown),D. Kim Turgeon,Phyllissa Schmiedlin‐Ren,Morton B. Brown,Wen-Sheng Guo,Stephen J. Rossi,Leslie Z. Benet,Paul B. Watkins	576
9	Expression of Enzymatically Active CYP3A4 by Caco-2 Cells Grown on Extracellular Matrix-Coated Permeable Supports in the Presence of 1α,25-Dihydroxyvitamin D3 1997 ·Molecular Pharmacology ·Phyllissa Schmiedlin‐Ren,Kenneth E. Thummel,Jeannine M. Fisher,Mary F. Paine,Kenneth S. Lown,Paul B. Watkins	276
10	Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. 1997 ·PubMed ·Phyllissa Schmiedlin‐Ren,David Edwards,Michael E. Fitzsimmons,Kan He,Kenneth S. Lown,Patrick M. Woster,Atiqur Rahman,Kenneth E. Thummel,Jeannine M. Fisher,Paul F. Hollenberg,Paul B. Watkins	108
11	Update of the Adult and Pediatric Liver Transplant Program at the University of Michigan. 1996 ·PubMed ·(unknown),John C. Magee,Jonathan S. Bromberg,Darrell A. Campbell,Chris J. Dickinson,Robert J. Fontana,(unknown),A. Craig Hillemeier,Anna S. Lok,Kenneth S. Lown,A. Olson,Jeffrey D. Punch,Grace L. Su,Robert M. Merion	4
12	Selective expression of CYP3A5 and not CYP3A4 in human blood 1996 ·Pharmacogenetics ·(unknown),Kenneth S. Lown,Phyllissa Schmiedlin‐Ren,Kenneth E. Thummel,Paul B. Watkins	38
13	The erythromycin breath test predicts the clearance of midazolam* 1995 ·Clinical Pharmacology & Therapeutics ·Kenneth S. Lown,Kenneth E. Thummel,Patrick E. Benedict,Danny D. Shen,D. Kim Turgeon,Stanley Berent,Paul B. Watkins	108
14	CYP3A gene expression in human gut epithelium 1994 ·Pharmacogenetics ·Joseph C. Kolars,Kenneth S. Lown,Phyllissa Schmiedlin‐Ren,Mita Ghosh,Che Fang,Steven Wrighton,Robert M. Merion,Paul B. Watkins	321
15	PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST 1994 ·Transplantation ·D. Kim Turgeon,Alan B. Leichtman,(unknown),Robert Schmouder,Kenneth S. Lown,Thomas M Annesley,Paul B. Watkins	19
16	P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients 1994 ·Clinical Pharmacology & Therapeutics ·D. Kim Turgeon,Alan B. Leichtman,Kenneth S. Lown,Daniel P. Normolle,G. Michael Deeb,Robert M. Merion,Paul B. Watkins	47
17	Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. 1994 ·Drug Metabolism and Disposition ·Kenneth S. Lown,Joseph C. Kolars,Kenneth E. Thummel,Jeffrey L. Barnett,Kent L. Kunze,Steven Wrighton,Paul B. Watkins	87
18	PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST 1994 ·Transplantation ·D. Kim Turgeon,Alan B. Leichtman,(unknown),Robert Schmouder,Kenneth S. Lown,Thomas M Annesley,Paul B. Watkins	15
19	Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity 1992 ·Clinical Pharmacology & Therapeutics ·Paul B. Watkins,D. Kim Turgeon,Paul Saenger,Kenneth S. Lown,Joseph C. Kolars,Ted Hamilton,(unknown),Philip S. Guzelian,John J. Voorhees	115
20	The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease 1992 ·Clinical Pharmacology & Therapeutics ·Kenneth S. Lown,Joseph C. Kolars,D. Kim Turgeon,Robert M. Merion,Steven Wrighton,Paul B. Watkins	108

About Kenneth S. Lown

Kenneth S. Lown is a scholar working on Pharmacology, Transplantation and Oncology, having authored 23 papers that have together received 3.0k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (9 papers) and Renal Transplantation Outcomes and Treatments (4 papers). The work is most often cited by research in Pharmacology (1.7k citations), Transplantation (258 citations) and Oncology (1.5k citations). Kenneth S. Lown has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Paul B. Watkins, Phyllissa Schmiedlin‐Ren, D. Kim Turgeon, Kenneth E. Thummel, Joseph C. Kolars, Steven Wrighton, Paul B. Watkins, Robert M. Merion, Mary F. Paine and Alan B. Leichtman. Their work appears in journals such as Journal of Clinical Investigation, Gastroenterology and Molecular Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact